BMY — BRISTOL MYERS SQUIBB CO catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

7 verified catalyst event(s) for BRISTOL MYERS SQUIBB CO (ticker BMY). Each is linked to its official source. Verified as of 2026-11-04.

Next verified catalyst

2026-11-18 — A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögr · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-11-18 in 14d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac Phase 3 · Sjögren's Syndrome	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-14 in 1mo ESTIMATED	READOUT Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Phase 2 · Heart Failure	BMY BRISTOL MYERS SQUIBB CO	BMS-986435	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-12-17 in 1mo ESTIMATED	READOUT Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Mon Phase 2 · Alzheimer Disease, Early Onset	BMY BRISTOL MYERS SQUIBB CO	BMS-986446	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-01-06 in 2mo ESTIMATED	READOUT A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickl Phase 1/2 · Anemia, Sickle Cell, Healthy Volunteers	BMY BRISTOL MYERS SQUIBB CO	BMS-986470, Famotidine, Pantoprazole	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-05 in 3mo ESTIMATED	READOUT A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination Phase 2 · Non-Small Cell Lung Cancer	BMY BRISTOL MYERS SQUIBB CO	Nivolumab, Ipilimumab, Carboplatin, Pacl	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-02-16 in 3mo ESTIMATED	READOUT A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced Phase 3 · Carcinoma, Non-Small-Cell Lung	BMY BRISTOL MYERS SQUIBB CO	Repotrectinib, Crizotinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2027-03-11 in 4mo ESTIMATED	READOUT A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Particip Phase 3 · Renal Cell Carcinoma	BMY BRISTOL MYERS SQUIBB CO	Nivolumab, Ipilimumab, Ipilimumab placeb	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change